453 related articles for article (PubMed ID: 29315922)
1. The use of omalizumab in allergen immunotherapy.
Dantzer JA; Wood RA
Clin Exp Allergy; 2018 Mar; 48(3):232-240. PubMed ID: 29315922
[TBL] [Abstract][Full Text] [Related]
2. Update on omalizumab in allergen immunotherapy.
Dantzer JA; Wood RA
Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):559-568. PubMed ID: 34419967
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab and hypersensitivity reactions.
Shankar T; Petrov AA
Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
[TBL] [Abstract][Full Text] [Related]
4. Oral Immunotherapy for Food Allergy.
Wood RA
J Investig Allergol Clin Immunol; 2017; 27(3):151-159. PubMed ID: 28102823
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.
Wood RA; Kim JS; Lindblad R; Nadeau K; Henning AK; Dawson P; Plaut M; Sampson HA
J Allergy Clin Immunol; 2016 Apr; 137(4):1103-1110.e11. PubMed ID: 26581915
[TBL] [Abstract][Full Text] [Related]
6. Combining anti-IgE with oral immunotherapy.
Lin C; Lee IT; Sampath V; Dinakar C; DeKruyff RH; Schneider LC; Nadeau KC
Pediatr Allergy Immunol; 2017 Nov; 28(7):619-627. PubMed ID: 28782296
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in children with severe allergic disease: a case series.
Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB
Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367
[TBL] [Abstract][Full Text] [Related]
8. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
Andorf S; Purington N; Block WM; Long AJ; Tupa D; Brittain E; Rudman Spergel A; Desai M; Galli SJ; Nadeau KC; Chinthrajah RS
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):85-94. PubMed ID: 29242014
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
10. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
J Allergy Clin Immunol; 2017 Oct; 140(4):1043-1053.e8. PubMed ID: 28414061
[TBL] [Abstract][Full Text] [Related]
12. Anti-IgE--emerging opportunities for Omalizumab.
Babu KS; Polosa R; Morjaria JB
Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.
Klunker S; Saggar LR; Seyfert-Margolis V; Asare AL; Casale TB; Durham SR; Francis JN;
J Allergy Clin Immunol; 2007 Sep; 120(3):688-95. PubMed ID: 17631952
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.
Yee CSK; Albuhairi S; Noh E; El-Khoury K; Rezaei S; Abdel-Gadir A; Umetsu DT; Burke-Roberts E; LeBovidge J; Schneider L; Rachid R
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):451-461.e7. PubMed ID: 30267889
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
De Filippo M; Votto M; Caminiti L; Carella F; Castro G; Landi M; Olcese R; Panasiti I; Vernich M; Barberi S; Ciprandi G; Marseglia GL
Allergol Immunopathol (Madr); 2022; 50(6):47-52. PubMed ID: 36335444
[TBL] [Abstract][Full Text] [Related]
16. Off-Label Uses of Omalizumab.
El-Qutob D
Clin Rev Allergy Immunol; 2016 Feb; 50(1):84-96. PubMed ID: 26048266
[TBL] [Abstract][Full Text] [Related]
17. The Use of Omalizumab in Food Oral Immunotherapy.
Labrosse R; Graham F; Des Roches A; Bégin P
Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):189-199. PubMed ID: 27628022
[TBL] [Abstract][Full Text] [Related]
18. Allergen immunotherapy as add-on to biologic agents.
Lombardi C; Canonica GW; Passalacqua G
Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):502-508. PubMed ID: 30148718
[TBL] [Abstract][Full Text] [Related]
19. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
20. Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.
Guilleminault L; Michelet M; Reber LL
Clin Rev Allergy Immunol; 2022 Feb; 62(1):216-231. PubMed ID: 34550555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]